Because Ars2‐reactive BCRs are expressed mostly in ABC‐type DLBCLs and account for roughly 25% in this subgroup, Ars2‐containing BAR‐bodies would be applicable only in a fraction of DLBCL patients. The gene discussed is SRRT; the disease is diffuse large B-cell lymphoma.